Anna Katherine Renfrew

Chattez avec Graph Search

Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.

AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.

The anticancer ruthenium-arene compd. [Ru(η6-C6H5CF3)(pta)Cl2] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane), termed RAPTA-CF3, with the electron-withdrawing α,α,α-trifluorotoluene ligand, is one of the most cytotoxic RAPTA compds. known. To ration ...

A series of compounds of general formula [Ru(eta(6)-fluoroarene)(pta)Cl-2] (fluoroarene = C6H5F, C6H5CF3, and 1,4-C6H4CH3F; pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane) have been prepared and characterized spectroscopically. Additionally, X-ray dif ...

The cationic complexes [(η6-arene)Ru(SC5H4NH)3]2+, arene being C6H6 (1), MeC6H5 (2), p-iPrC6H4Me (3) or C6Me6 (4), have been synthesized from the reaction of 4-pyridinethiol with the corresponding precursor (η6-arene)2Ru2(μ2-Cl)2Cl2 and isolated as the chl ...

The rational development of multinuclear arene ruthenium complexes (arene = p-cymene, hexamethylbenzene) from generation 1 (G1) and generation 2 (G2) of 4-iminopyridyl based poly(propyleneimine) dendrimer scaffolds of the type, DAB-(NH2)n (n = 4 or 8, DAB ...

In recent years, ruthenium-based antitumour drugs have emerged as an attractive alternative to cisplatin, exhibiting both excellent activity in tumours where cisplatin is of limited use and low general toxicity, leading to reduced side effects. Two rutheni ...

Cationic arene ruthenium-based tetranuclear complexes comprising rectangular structures have been obtained from the dinuclear arene ruthenium complexes [Ru2(arene)2(OO.intrsec.OO)2Cl2] (arene = p-cymene, hexamethylbenzene; OO.intrsec.OO = 2,5-dihydroxy-1,4 ...

Pyridylferrocene and imidazolylferrocene arene-Ru complexes [Ru(η6-arene)(L)Cl2] where L = NC5H4CH2NHOCC5H4FeC5H5, arene = p-iPrC6H4Me (1) or C6Me6 (2); L = NC3H3N(CH2)2O2CC5H4FeC5H5, arene = p-iPrC6H4Me (3) or C6Me6 (4), and diruthenium-arene complexes [R ...

The polar phosphinyl carboxamide, 1'-(diphenylphosphino)-1-[N-(2-hydroxyethyl)carbamoyl]ferrocene [I; Z = null; (1)] , reacts readily with H2O2 and elemental S to give the corresponding phosphine oxide I [Z = O (2)] and phosphine sulfide I [Z = S (3)], res ...

Ruthenium-based compounds are an attractive alternative to clinically used platinum drugs due to several features including a wide range of accessible oxidation states, varied synthetic chemistry and typically lower general toxicities. One series of ruthen ...

Arene ruthenium complexes contg. long-chain N-ligands L1 = NC5H4-4-COO-C6H4-4-O-(CH2)9-CH3 or L2 = NC5H4-4-COO-(CH2)10-O-C6H4-4-COO-C6H4-4-C6H4-4-CN derived from isonicotinic acid, of the type [(arene)Ru(L)Cl2] (arene = C6H6, L = L1: 1; arene = p-MeC6H4Pr ...

[M(η6-arene)(ptn)Cl]X (M = Ru, Os; arene = p-cymene, benzene, toluene, hexamethylbenzene; ptn = 3,7-dimethyl-7-phospha-1,3,5-triazabicyclo[3.3.1]nonane; X = Cl-, BF4-) were prepd. and characterized spectroscopically. X-ray diffraction was addnl. used to ch ...

The self-assembly of 2,4,6-tris(pyridin-4-yl)-1,3,5-triazine (tpt) triangular panels with p-cymene (p-PriC6H4Me) ruthenium building blocks and 2,5-dioxydo-1,4-benzoquinonato (dobq) bridges, in the presence of a functionalized pyrenyl deriv. (pyrene-R), aff ...

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the dev ...

[Ru(η6-arene)(pta)(PR3)Cl]BF4 (arene = p-cymene or 4-phenyl-2-butanol; pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane, PR3 = PPh2(p-C6H4C2H4C8F17), PPh(p-C6H4C2H4C8F17)2, P(p-C6H4C2H4C6F13)3, PPh3 or P(p-C6H4F)3) were prepd. and characterized by spect ...

Caught in the act: The first stable η4-diseleno-p-benzoquinone complex, [Cp*lr(η4-C6H4Se2)], has been isolated. The X-ray structure confirms the coordination of the elusive diselenobenzoquinone intermediate. The anticancer activity of this complex was comp ...

Metal complexes bearing phosphine ligands are attracting increasing attention for their applications in medicinal chem. In particular, organometallic ruthenium-phosphine complexes have been found to exhibit promising antitumor activity. The synthesis, anti ...

A series of compds. of general formula [Ru(.eta.6-p-cymene) (R2acac)(PTA)][X] (R2acac = Me2acac, tBu2acac, Ph2acac, Me2acac-Cl; PTA = 1,3,5-triaza-7-phosphaadamantane; X = BPh4, BF4), and the precursor to the Me2acac-Cl deriv. [Ru(.eta.6-p-cymene)(Me2acac- ...

The cytotoxicities of the large cationic arene-ruthenium prismatic cage [Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+ (tpt = 2,4,6-tris(pyridin-4-yl)-1,3,5-triazine, dhbq = 2,5-dihydroxy-1,4-benzoquinolato; 16+), and its "complex-in-a-complex" derivs. [(acac)2M-1]6+ ...

Anna Katherine Renfrew

Chattez avec Graph Search

Metabolization of [Ru(η6-C6H5CF3)(pta)Cl2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand

Tuning the efficacy of ruthenium(II)-arene (RAPTA) antitumour compounds with fluorinated arene ligands

Water-soluble arene ruthenium complexes containing pyridinethiolato ligands: Synthesis, molecular structure, redox properties and anticancer activity of the cations [(η6-arene)Ru(p-SC5H4NH)3]2+

Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds

Novel organometallic ruthenium complexes for selective activation in tumour cells

Synthesis, Molecular Structure, and Anticancer Activity of Cationic Arene Ruthenium Metallarectangles

Arene-ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type [Ru(η6-arene)(NC5H4CH2NHOC-C5H4FeC5H5)Cl2] and [Ru(η6-arene)(NC3H3N(CH2)2O2C-C5H4FeC5H5)Cl2]

Synthesis and anticancer activity of chalcogenide derivatives and platinum(II) and palladium(II) complexes derived from a polar ferrocene phosphanyl-carboxamide

Ruthenium(II) Arene Compounds as Versatile Anticancer Agents

Synthesis and Anticancer Activity of Long-Chain Isonicotinic Ester Ligand-Containing Arene Ruthenium Complexes and Nanoparticles

Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta

Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Use of Perfluorinated Phosphines to Provide Thermomorphic Anticancer Complexes for Heat-Based Tumor Targeting

Discovery, structure, and anticancer activity of an iridium complex of diselenobenzoquinone

Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(η6-cymene)(PPh2(o-C6H4O)-κ2-P,O)(pta)]+ and an investigation of its cytotoxic effects

Influence of the diketonato ligand on the cytotoxicities of [Ru(.eta.6-p-cymene)(R2acac)(PTA)]+ complexes (PTA = 1,3,5-triaza-7-phosphaadamantane)

The "complex-in-a-complex" cations [(acac)2M.cntnd.Ru6-(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: a trojan horse for cancer cells